Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells

Experimental Eye Research

Volumn 122, Issue , 2014, Pages 20-31

  Deissler, Heidrun L ^a   Lang, Gerhard K ^a   Lang, Gabriele E ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Aflibercept; Antibody internalization; Diabetic retinopathy; Neovascularization; Permeability; Ranibizumab; Retinal endothelial cells; VEGF inhibition

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CLAUDIN 1; IMMUNOGLOBULIN G; PLACENTAL GROWTH FACTOR; RITUXIMAB; VASCULOTROPIN A;

ARTICLE; BINDING AFFINITY; CELL FRACTIONATION; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL ORGANELLE; CELL PROLIFERATION; CONTROLLED STUDY; INHIBITION KINETICS; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; RETINA CELL; WESTERN BLOTTING;

AFLIBERCEPT; ANTIBODY INTERNALIZATION; DIABETIC RETINOPATHY; NEOVASCULARIZATION; PERMEABILITY; RANIBIZUMAB; RETINAL ENDOTHELIAL CELLS; VEGF INHIBITION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CATTLE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CLAUDIN-1; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; IMMUNOLOGIC FACTORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84896968297     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2014.02.024     Document Type: Article

References (43)

1. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N.Engl. J. Med. 1994, 331:1480-1487.
2. Arevalo J.F., Sanchez J.G., Lasave A.F., Wu L., Maia M., Bonafonte S., Brito M., Alezzandrini A.A., Restrepo N., Berrocal M.H., Saravia M., Farah M.E., Fromow-Guerra J., Morales-Canton V. Intravitreal bevacizumab (Avastin) for diabetic retinopathy: the 2010 GLADAOF lecture. J.Ophthalmol. 2011, 1-13. 2011: Article ID 584238, 584238. 10.1155/2011/584238.
3. Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb. Haemost. 2006, 95:36-42.
4. Cai J., Wu L., Qi X., Shaw L., Li Calzi S., Caballero S., Jiang W.G., Vinores S.A., Antonetti D., Ahmed A., Grant M.B., Boulton M.E. Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One 2011, 6(3):e18076. 10.1371/journal.pone.0018076.
5. Castellon R., Hamdi H.K., Sacerio I., Aoki A.M., Kenney M.C., Ljubimov A.V. Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp. Eye Res. 2002, 74:523-535.
6. Coffey G.P., Stefanich E., Palmieri S., Eckert R., Padilla-Eagar J., Fielder P.J., Pippig S. Invitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J.Pharmacol. Exp. Ther. 2004, 310:896-904.
7. Daugas E., Nochy D., Ravagnan L., Loeffler M., Susin S.A., Zamzami N., Kroemer G. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett. 2000, 476:118-123.
8. Deissler H.L., Deissler H., Lang G.K., Lang G.E. Generation and characterization of iBREC: novel hTERT-immortalized bovine retinal endothelial cells. Int. J. Mol. Med. 2005, 15:65-70.
9. Deissler H.L., Kuhn E.M., Lang G.E., Deissler H. Tetraspanin CD9 is involved in the migration of retinal microvascular endothelial cells. Int. J. Mol. Med. 2007, 20:643-652.
10. ®) in microvascular retinal endothelial cells. Br. J. Ophthalmol. 2008, 92:839-843.
11. 165 on tight junction protein claudin-1 and permeability in microvascular retinal endothelial cells. Investig. Ophthalmol. Vis. Sci. 2010, 51:535-542.
12. Deissler H.L., Deissler H., Lang G.E. Inhibition of VEGF is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells. Br. J. Ophthalmol. 2011, 95:1151-1156.
13. Deissler H.L., Deissler H., Lang G.E. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences. Br. J. Ophthalmol. 2012, 96:1023-1028.
14. Deissler H.L., Deissler H., Lang G.K., Lang G.E. Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells. Graefes Arch. Clin. Exp. Ophthalmol. 2013, 251:2345-2353.
15. Deissler H.L., Deissler H., Lang G.K., Lang G.E. VEGF but not PlGF disturbs the barrier of retinal endothelial cells. Exp. Eye Res. 2013, 115:162-171.
16. Do D.V., Nguyen Q.D., Boyer D., Schmidt-Erfurth U., Brown D.M., Vitti R., Berliner A.J., Gao B., Zeitz O., Ruckert R., Schmelter T., Sandbrink R., Heier J.S. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012, 119:1658-1665. DA VINCI Study Group.
17. Ellgard L., Ruddock L.W. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep. 2005, 6:28-32.
18. Ferrara N., Damico L., Shams N., Lowman H., Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006, 26:859-870.
19. Fujii H., Nakatani K., Arita N., Ito M.R., Terada M., Miyazaki T., Yoshida M., Ono M., Fujiwara T., Saiga K., Ota T., Ohtani H., Lockwood M., Sasaki T., Nose M. Internalization of antibodies by endothelial cells via fibronectin implicating a novel mechanism in lupus nephritis. Kidney Int. 2003, 64:1662-1670.
20. Gao Y.S., Sztul E. Monoclonal antibodies as context-specific reagents: differential antigen reactivity of MAb 58K-9 during immunoprecipitation, immunoblotting, and immunofluorescence analyses. Hybridoma 1999, 18:479-485.
21. Harhaj N.S., Felinski E.A., Wolpert E.B., Sundstrom J.M., Gardner T.W., Antonetti D.A. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Investig. Ophthalmol. Vis. Sci. 2006, 47:5106-5115.
22. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., Rudge J.S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11393-11398.
23. 165 and heparin: explanation for deposits observed on endothelial veins in monkey eyes. Br. J. Ophthalmol. 2013, 97:511-517.
24. Kacskovics I., Kis Z., Mayer B., West A.P., Tiangco N.E., Tilahun M., Cervenak L., Bjorkman P.J., Goldsby R.A., Szenci O., Hammarström L. FcRn mediates elongated serum half-life of human IgG in cattle. Int. Immunol. 2006, 18:525-536.
25. Khaliq A., Foreman D., Ahmed A., Weich H., Gregor Z., McLeod D., Boulton M. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab. Investig. 1998, 78:109-115.
26. Kim H., Fariss R.N., Zhang C., Robinson S.B., Thill M., Csaky K.G. Mapping of the neonatal Fc receptor in the rodent eye. Investig. Ophthalmol. Vis. Sci. 2008, 49:2025-2029.
27. Klettner A., Kruse M.L., Meyer T., Wesch D., Kabelitz D., Roider J. Different properties of VEGF-antagonists: bevacizumab but not Ranibizumab accumulates in RPE cells. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:1601-1608.
28. Klettner A., Möhle F., Roider J. Intracellular Bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:819-824.
29. Kobayashi T., Vischer U.M., Rosnoblet C., Lebrand C., Lindsay M., Parton R.G., Kruithof E.K.O., Gruenberg J. The tetraspanin CD63/lamp3 cycles between endocytic and secretory compartments in human endothelial cells. Mol. Biol. Cell 2000, 11:1829-1843.
30. Kuo J.-C. Mechanotransduction at focal adhesions: integrating cytoskeletal mechanics in migrating cells. J.Cell. Mol. Med. 2013, 17:704-712.
31. Mitchell P., Bandello F., Schmidt-Erfurth U., Lang G.E., Massin P., Schlingemann R.O., Sutter F., Simader C., Burian G., Gerstner O., Weichselberger A. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011, 118:615-625. RESTORE study group.
32. Miura Y., Klettner A., Roider J. VEGF antagonists decrease barrier function of retinal pigment epithelium invitro: possible participation of intracellular glutathione. Investig. Ophthalmol. Vis. Sci. 2010, 51:4848-4855.
33. Muzykantov V.R., Atochina E.N., Kuo A., Barnathan E.S., Notarfrancesco K., Shuman H., Dodia C., Fischer A.B. Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme. Am. J. Physiol 1996, 270:L704-L713. (Lung Cell. Mol. Physiol. 14).
34. Nguyen Q.D., Tatlipinar S., Shah S.M., Haller J.A., Quinlan E., Sung J., Zimmer-Galler I., Do D.V., Campochiaro P.A. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol. 2006, 142:961-969.
35. Papadopoulos N., Martin J., Ruan Q., Rafique A., Rosconi M.P., Shi E., Pyles E.A., Yancopoulos G.D., Stahl N., Wiegand S.J. Binding and neutralization of vascular endothelial growth fact (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012, 15:171-185.
36. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57:4593-4599.
37. Qaum T., Xu Q., Joussen A.M., Clemens M.W., Qin W., Miyamoto K., Hassessian H., Wiegand S.J., Rudge J., Yancopoulos G.D., Adamis A.P. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Investig. Ophthalmol. Vis. Sci. 2001, 42:2408-2413.
38. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of B cells invivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
39. Ronda N., Gatti R., Orlandini G., Borghetti A. Binding and internalization of human IgG by living cultured endothelial cells. Clin. Exp. Immunol. 1997, 109:211-216.
40. Stewart E.A., Samaranayake G.J., Browning A.C., Hopkinson A., Amoaku W.M. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF-isoforms and anti-VEGF treatment. Exp. Eye Res. 2011, 93:761-766.
41. Tretiach M., van Driel D., Gillies M.C. Transendothelial electrical resistance of bovine retinal capillary endothelial cells is influenced by cell growth patterns: an ultrastructural study. Clin. Exp. Ophthalmol. 2003, 31:348-353.
42. Wisniewska-Kruk J., Hoeben K.A., Vogels I.M., Gaillard P.J., Van Noorden C.J., Schlingemann R.O., Klaassen I. Anovel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes. Exp. Eye Res. 2012, 96:181-190.
43. Yu L., Hiang X.H., Ferrara N. Comparing protein VEGF inhibitors: invitro biological studies. Biochem. Biophys. Res. Commun. 2011, 408:276-281.